[fcb5af]: / literature / by_gene_clean / CD274.tsv

Download this file

# pmid doi year title Hugo_Symbol
1 32401663 10.1080/15513815.2020.1764680 2022 PD-L1 and PD-L2 Mutations in Pediatric Hodgkin Lymphoma: Do They Have Any Prognostic Significance? CD274
2 34520052 10.1111/bjh.17793 2022 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial. CD274
3 34842351 10.1002/cam4.4462 2022 PD-L1 expression is associated with the spontaneous regression of patients with methotrexate-associated lymphoproliferative disorders. CD274
4 34862664 10.1111/apm.13195 2022 Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population. CD274
5 34959071 10.1016/j.molimm.2021.12.014 2022 HomA and HomB, outer membrane proteins of Helicobacter pylori down-regulate activation-induced cytidine deaminase (AID) and Ig switch germline transcription and thereby affect class switch recombination (CSR) of Ig genes in human B-cells. CD274
6 34996890 10.1038/s41598-021-02515-5 2022 The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma. CD274
7 35032188 10.1007/s00277-022-04760-8 2022 Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia-lymphoma. CD274
8 35165282 10.1038/s41467-022-28479-2 2022 EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1. CD274
9 35194801 10.1111/bjd.21063 2022 Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and Sézary syndrome: association with disease stage and clinical outcome. CD274
10 35344582 10.1182/blood.2021014007 2022 Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignancies. CD274
11 35359004 10.1182/bloodadvances.2022007104 2022 SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. CD274
12 35417939 10.3324/haematol.2021.280352 2022 Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma. CD274
13 35655072 10.1038/s41598-022-13101-8 2022 Plasma extracellular vesicles bearing PD-L1, CD40, CD40L or TNF-RII are significantly reduced after treatment of AIDS-NHL. CD274
14 35680804 10.19746/j.cnki.issn.1009-2137.2022.03.018 2022 [Inhibitory Effect of Interference with PD-L1 Expression on B-cell lymphoma in Mice]. CD274
15 35741318 10.3390/diagnostics12061507 2022 Hodgkin Lymphoma: Biology and Differential Diagnostic Problem. CD274
16 35764886 10.1038/s41598-022-15162-1 2022 Mutations in the miR-142 gene are not common in myeloproliferative neoplasms. CD274
17 35767735 10.1182/bloodadvances.2022007046 2022 The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade. CD274
18 35774848 10.1155/2022/3276925 2022 Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics. CD274
19 35789115 10.1111/his.14718 2022 Hodgkinoid histiocytosis: an atypical nodal CD30 and S100-positive histiocytosis with eosinophilia. CD274
20 35848760 10.1097/PAS.0000000000001899 2022 9p24.1 Genetic Alteration and PD-L1 Expression Are Characteristic of De Novo and Methotrexate-associated Epstein-Barr Virus-positive Hodgkin Lymphoma, But Not Methotrexate-associated Hodgkin-like Lesions. CD274
21 35922773 10.1186/s12885-022-09803-x 2022 Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma. CD274
22 32803453 10.1007/s00428-020-02901-w 2021 Clinicopathological analysis of neoplastic PD-L1-positive EBV<sup>+</sup> diffuse large B cell lymphoma, not otherwise specified, in a Japanese cohort. CD274
23 32871584 10.1182/blood.2020006464 2021 Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. CD274
24 32964767 10.1080/10428194.2020.1821011 2021 Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas. CD274
25 33028589 10.1158/1078-0432.CCR-20-1457 2021 CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma. CD274
26 33091534 10.1016/j.canlet.2020.10.024 2021 NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma. CD274
27 33184699 10.1007/s00262-020-02787-2 2021 Epstein-Barr virus recruits PDL1-positive cells at the microenvironment in pediatric Hodgkin lymphoma. CD274
28 33232972 10.1182/blood.2020005244 2021 Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas. CD274
29 33247999 10.1111/cas.14752 2021 Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer. CD274
30 33277223 10.1016/j.clml.2020.11.009 2021 Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma. CD274
31 33299141 10.1038/s41375-020-01105-0 2021 Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression. CD274
32 33369766 10.1002/hon.2836 2021 Pembrolizumab for refractory primary mediastinal B-cell lymphoma with central nervous system involvement. CD274
33 33389078 10.1007/s00432-020-03446-w 2021 Vincristine upregulates PD-L1 and increases the efficacy of PD-L1 blockade therapy in diffuse large B-cell lymphoma. CD274
34 33480087 10.1002/hon.2839 2021 High-grade B-cell lymphomas with MYC and BCL2 translocations lack tumor-associated macrophages and PD-L1 expression: A possible noninflamed subgroup. CD274
35 33512416 10.1182/blood.2020007245 2021 Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma. CD274
36 33517324 10.2967/jnumed.120.258384 2021 Synthesis and Preclinical Evaluation of a <sup>68</sup>Ga-Labeled Adnectin, <sup>68</sup>Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression. CD274
37 33558066 10.1016/j.pathol.2020.11.004 2021 CD68-positive tumour associated macrophages, PD-L1 expression, and EBV latent infection in a high HIV-prevalent South African cohort of Hodgkin lymphoma patients. CD274
38 33590326 10.1007/s00595-021-02236-2 2021 Immunotherapeutic advances in gastric cancer. CD274
39 33620088 10.1111/bjh.17362 2021 Soluble PD-L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma. CD274
40 33674274 10.1158/1078-0432.CCR-21-0133 2021 Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy. CD274
41 33686666 10.1111/bjh.17366 2021 Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors. CD274
42 33691262 10.1016/j.ejca.2021.01.020 2021 Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma. CD274
43 33721375 10.1111/ejh.13621 2021 Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies. CD274
44 33764958 10.12659/MSM.929431 2021 Knockdown of Chitinase 3-Like-1 Inhibits Cell Proliferation, Promotes Apoptosis, and Enhances Effect of Anti-Programmed Death Ligand 1 (PD-L1) in Diffuse Large B Cell Lymphoma Cells. CD274
45 33807678 10.3390/jof7030186 2021 Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies. CD274
46 33889438 10.1080/2162402X.2021.1907059 2021 VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma. CD274
47 33918793 10.3390/cancers13081801 2021 Clinical Applications of Genomic Alterations in ATLL: Predictive Markers and Therapeutic Targets. CD274
48 33941556 NA 2021 PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation. CD274
49 33972504 10.1038/s41408-021-00477-5 2021 Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. CD274
50 34021249 10.1038/s41375-021-01289-z 2021 Thyroid MALT lymphoma: self-harm to gain potential T-cell help. CD274
51 34077007 NA 2021 Clinical significance of PD-1 and PD-L1 molecules in patients with diffuse large B-cell lymphoma, not otherwise specified: Correlation with clinical and pathological findings. CD274
52 34078046 10.3760/cma.j.cn112151-20201223-00953 2021 [Genetic abnormality and protein expression of C-MYC and PD-L1 in ALK-negative anaplastic large cell lymphoma]. CD274
53 34130989 10.1136/jitc-2021-002558 2021 Pan-cancer analysis of <i>CD274</i> (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression. CD274
54 34153661 10.1016/j.intimp.2021.107870 2021 PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma. CD274
55 34181355 10.31557/APJCP.2021.22.6.1943 2021 NFATc1 is Suppressed in Tumor Microenvironment of Hodgkin Lymphoma. CD274
56 34327781 10.1111/cas.15091 2021 Current progress and future perspectives of research on intravascular large B-cell lymphoma. CD274
57 34363798 10.1016/j.humpath.2021.07.011 2021 Clinicopathological features and prognostic significance of programmed death ligand 1 in pediatric ALK-positive anaplastic large cell lymphoma: results of the ALCL99 treatment in Japan. CD274
58 34405609 10.3760/cma.j.cn112151-20210110-00023 2021 [Characteristics of PD-L1 expression in tumor cells and tumor microenvironment of DLBCL with MYD88 L265P mutation]. CD274
59 34534136 10.1097/PAS.0000000000001809 2021 Clinicopathologic Analysis of Primary Adrenal Diffuse Large B-Cell Lymphoma: A Reappraisal of 23 Japanese Patients Based on EBV Association and PD-L1 Expression in Tumor Cells. CD274
60 34543472 10.1002/hon.2926 2021 Combined tumor-associated macrophages biomarker predicting extremely poor outcome of patients with primary central nervous system lymphoma. CD274
61 34584457 10.2147/CMAR.S317319 2021 Myelin and Lymphocyte Protein (MAL): A Novel Biomarker for Uterine Corpus Endometrial Carcinoma. CD274
62 34615710 10.1073/pnas.2105822118 2021 Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma. CD274
63 34649362 10.1016/j.biopha.2021.112238 2021 An evidence mapping and scientometric analysis of the top-100 most cited clinical trials of anti-PD-1/PD-L1 drugs to treat cancers. CD274
64 34661162 10.1158/2643-3230.BCD-21-0044 2021 Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1. CD274
65 34742294 10.1186/s13000-021-01163-7 2021 Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers. CD274
66 34955650 10.2147/IJGM.S341557 2021 Combined Identification of Novel Markers for Diagnosis and Prognostic of Classic Hodgkin Lymphoma. CD274
67 31163235 10.1016/j.jaad.2019.05.077 2020 Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review. CD274
68 31330525 10.1159/000500974 2020 Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance. CD274
69 31383967 10.1038/s41379-019-0336-3 2020 PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma. CD274
70 31493237 10.1007/s00535-019-01616-3 2020 Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma. CD274
71 31653980 10.1038/s41379-019-0392-8 2020 Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression. CD274
72 31699300 10.1016/j.pathol.2019.09.005 2020 Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis. CD274
73 31709594 10.1002/cbf.3463 2020 Epigenetic abnormalities of classical Hodgkin lymphoma and its effect on immune escape. CD274
74 31752573 10.1080/10428194.2019.1691200 2020 New murine models of aggressive lymphoma. CD274
75 31787352 10.1016/j.imbio.2019.11.007 2020 Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma. CD274
76 31790142 10.1182/blood.2019000847 2020 The immune landscape and response to immune checkpoint blockade therapy in lymphoma. CD274
77 31811434 10.1007/s00428-019-02695-6 2020 Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas. CD274
78 31812554 10.1016/S1470-2045(19)30671-0 2020 Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. CD274
79 31825135 10.1002/1878-0261.12616 2020 High CD206 levels in Hodgkin lymphoma-educated macrophages are linked to matrix-remodeling and lymphoma dissemination. CD274
80 31829043 10.2217/fon-2019-0468 2020 Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. CD274
81 31879046 10.1016/j.prp.2019.152703 2020 TLR9 expression is associated with PD-L1 expression and indicates a poor prognosis in patients with peripheral T-cell lymphomas. CD274
82 31894883 10.1111/pin.12891 2020 Diagnostic utility of programmed cell death ligand 1 (clone SP142) in mediastinal composite lymphoma: A report of two cases. CD274
83 31894892 10.1111/pin.12888 2020 Syncytial variant of classic Hodgkin lymphoma: Four cases diagnosed with the aid of CD274/programmed cell death ligand 1 immunohistochemistry. CD274
84 31903640 10.1002/jcla.23173 2020 Adrenal diffuse large B-cell lymphoma with high PD-L1 expression: Two case reports and literature review. CD274
85 31911188 10.1016/j.semcancer.2020.01.001 2020 Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance. CD274
86 31911474 10.1073/pnas.1908158117 2020 High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model. CD274
87 31977037 10.1093/ajcp/aqz198 2020 Immunohistochemical Assessment of the Diagnostic Utility of PD-L1 (Clone SP142) for Methotrexate-Associated Lymphoproliferative Disorders With an Emphasis of Neoplastic PD-L1 (Clone SP142)-Positive Classic Hodgkin Lymphoma Type. CD274
88 31983543 10.1016/j.beem.2019.101370 2020 New insight in endocrine-related adverse events associated to immune checkpoint blockade. CD274
89 31992262 10.1186/s12885-020-6550-z 2020 Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis. CD274
90 32030732 10.1111/bjh.16494 2020 Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy. CD274
91 32054467 10.1186/s12885-020-6612-2 2020 Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma. CD274
92 32066566 10.1158/0008-5472.CAN-19-2948 2020 Revisiting Immunotherapy: A Focus on Prostate Cancer. CD274
93 32089543 10.1038/s41375-020-0737-9 2020 PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma. CD274
94 32116068 10.1080/17474086.2020.1733405 2020 Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma. CD274
95 32143684 10.1186/s13104-020-04975-w 2020 Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease. CD274
96 32157792 10.1002/1878-0261.12664 2020 Overexpression of GLT1D1 induces immunosuppression through glycosylation of PD-L1 and predicts poor prognosis in B-cell lymphoma. CD274
97 32170448 10.1007/s00428-020-02790-z 2020 Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified. CD274
98 32248797 10.1186/s12885-020-06755-y 2020 PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma. CD274
99 32295735 10.1016/j.clml.2019.11.021 2020 The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma. CD274
100 32366559 NA 2020 Plasmablastic Lymphomas: Characterization of Tumor Microenvironment Using CD163 and PD-1 Immunohistochemistry. CD274